Forte Biosciences seeks Nasdaq delisting, plans to end SEC reporting after merger closes - FBRX News | RalliesForte Biosciences seeks Nasdaq delisting, plans to end SEC reporting after merger closes
F
FBRX• Forte Biosciences seeks Nasdaq delisting after merger closes
- Forte Biosciences requested Nasdaq suspend trading and delist its shares following completion of its merger on Aug. 27, 2026.
- Nasdaq is expected to file Form 25 to remove the stock from listing and deregister it under Exchange Act Section 12(b).
- A Form 15 filing is planned to terminate registration under Section 12(g) and suspend SEC reporting duties under Sections 13 and 15(d).
